[Nearshore Protein: AI-enabled high-throughput wet experiments and data package services are still in the early stages of market expansion] On October 7, Nearshore Protein (688137.SH) issued a serious abnormal stock trading fluctuation and risk warning announcement. The company's 2025 RNA vaccine drug-related product revenue will account for 11.38% of total product revenue, which is a relatively low proportion. The company's AI-enabled high-throughput wet experiments and data package services are still in the early stages of market expansion, and as of the first half of 2026, related business revenue will account for less than 2% of the company's overall operating income. Given that the application of AI in the drug R&D industry is still in its infancy, there are risks such as rapid technology iteration, long industry verification cycles, and difficulty in commercialization, and there are significant uncertainties in the company's future related revenue and profit realization.